A group of scientists has developed a new gel that can not only destroy brain cancer (glioblastoma), but also prevent the tumors from returning. In testing on animal models, this drug has succeeded in treating all samples.
Researchers at Johns Hopkins University have developed an anti-cancer gel that, according to them, probably The most effective treatment for glioblastoma throughout history; Because this gel can prevent tumor growth even in parts of the brain where traditional anticancer treatments and surgery do not work.
“We usually 100% survival rate We don’t see it in mice with this disease.” As a result, this treatment can be very important and decisive for patients.
Currently, an FDA-approved brain implant called Giladel is the most popular treatment for glioblastoma. Their new gel performed even better than Giladel, says Professor Tyler, who was involved in the development of that implant in the 1990s.
This new gel fights cancer in two ways
The reason for the success of this treatment is probably because this new gel works both ways Chemotherapy and immunotherapy implements This product is made with the combination of Paclitaxel anticancer drug and aCD47 antibody.
The first drug is a chemotherapy drug used in ovarian, lung and breast cancer. The second drug also attacks macrophages, which help tumors grow by protecting cancer cells.
In their experiments, the researchers first removed the tumors from the brain and then filled their place with gel. This made the cancer cells unable to grow again and form a tumor. Additionally, when scientists tried to manually plant tumors in the brains of mice, the immune system kicked in and killed the cancer cells without the need for drug or therapeutic intervention.
Of course, experiments have shown that this method is not highly effective without surgery. When the researchers placed the gel directly on the tumors without surgery, only 50 percent of the samples survived. The absence of tumors apparently gives the gel enough time to activate.
Researchers are now planning to start clinical trials on humans. The results of this research have been published in the journal PNAS.
